Lilly, co-market leader with Novo with its obesity drug Zepbound, has started exploring the use of GLP-1s for AUD and in October last year launched a Phase III trial of brenipatide, a GLP-1/GIP candidate, in patients with the condition
Chain pharmacies and hospital pharmacies undergo regular inspection of their cold storage equipment
The study was funded by Novo Nordisk, which designed and oversaw the trial
In women with polycystic ovary syndrome (PCOS) , weight loss can paradoxically improve menstrual regularity by reducing insulin resistance and androgen levels
In this study, no effect of pioglitazone on liver fibrosis was shown
Thyroid Health: A major contraindication for any glp-1 receptor agonist (including dual and triple agonists) is a personal or family history of Medullary Thyroid Carcinoma (MTC)